12:00 AM
 | 
Mar 08, 1999
 |  BC Week In Review  |  Company News  |  Deals

Corvas, Schering-Plough deal

CVAS reacquired the exclusive development and commercialization rights to recombinant Nematode Anticoagulant Protein 5 (rNAP5) covered in the companies' 1994 agreement....

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >